Atorvastatin 40mg in patients with relapsing-remitting multiple sclerosis treated with interferon-beta-1b (SWAMBIMS)

Authors Insel Gruppe AG, University Hospital Bern -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
Links ClinicalTrials.gov
Title: Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with relapsing-remitting multiple sclerosis treated with interferon-beta-1b SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis Short title: \"SWABIMS\" Study phase: Phase IIb study Study design: Multi-center, randomized, rater-blinded, parallel-group-study in Switzerland Investigational product: Atorvastatin 40mg every day (oral) plus Interferon-beta Reference product: Interferon-beta-1b 250mg given Indication: Relapsing-remitting multiple sclerosis (RR-MS) Study objectives: Comparison of efficacy, safety and tolerability of combination of Atorvastatin 40mg (per os) daily and Interferon-beta-1b e.o.d in patients with relapsing-remitting multiple sclerosis compared to monotherapy with Interferon-beta-1b e.o.d. Primary Endpoint: Proportion of patients with new T2 lesions after 15 months of treatment.
Epistemonikos ID: bf7691ced2375686496663711594bcb3f69ad3f5
First added on: Mar 31, 2022